309
Views
16
CrossRef citations to date
0
Altmetric
Gestational Diabetes

Circulating levels of Elabela and Apelin in the second and third trimesters of pregnancies with gestational diabetes mellitus

, , ORCID Icon, , , , , , , , , & ORCID Icon show all
Pages 890-894 | Received 14 Nov 2019, Accepted 03 Mar 2020, Published online: 25 Mar 2020

References

  • Johns EC, Denison FC, Norman JE, et al. Gestational diabetes mellitus: mechanisms, treatment, and complications. Trends Endocrinol Metab. 2018;29(11):743–754.
  • Guariguata L, Linnenkamp U, Beagley J, et al. Global estimates of the prevalence of hyperglycaemia in pregnancy. Diabetes Res Clin Pract. 2014;103(2):176–185.
  • Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest. 2005;115(3):485–491.
  • Chu SY, Callaghan WM, Kim SY, et al. Maternal obesity and risk of gestational diabetes mellitus. Diabetes Care. 2007;30(8):2070–2076.
  • Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85–97.
  • Fasshauer M, Blüher M, Stumvoll M. Adipokines in gestational diabetes. Lancet Diabetes Endocrinol. 2014;2(6):488–499.
  • Hu H, He L, Li L, et al. Apelin/APJ system as a therapeutic target in diabetes and its complications. Mol Genet Metab. 2016;119(1–2):20–27.
  • Bellos I, Fitrou G, Pergialiotis V, et al. Serum levels of adipokines in gestational diabetes: a systematic review. J Endocrinol Invest. 2019;42(6):621–631.
  • Dray C, Knauf C, Daviaud D, et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab. 2008;8(5):437–445.
  • Bao W, Baecker A, Song Y, et al. Adipokine levels during the first or early second trimester of pregnancy and subsequent risk of gestational diabetes mellitus: a systematic review. Metabolism. 2015;64(6):756–764.
  • Elsehmawy A, El-Toukhy SE, Seliem N, et al. Apelin and chemerin as promising adipokines in children with type 1 diabetes mellitus. Diabetes Metab Syndr Obes. 2019;12:383–389.
  • Eberlé D, Marousez L, Hanssens S, et al. Elabela and Apelin actions in healthy and pathological pregnancies. Cytokine Growth Factor Rev. 2019;46:45–53.
  • Zhang Y, Wang Y, Lou Y, et al. Elabela, a newly discovered APJ ligand: similarities and differences with apelin. Peptides. 2018;109:23–32.
  • Hassan SS, Gomez-Lopez N. Reducing maternal mortality: can Elabela help in this fight. Lancet. 2019;394(10192):8–9.
  • Wang Z, Yu D, Wang M, et al. Elabela-apelin receptor signaling pathway is functional in mammalian systems. Sci Rep. 2015;5(1):8170.
  • Kuba K, Sato T, Imai Y, et al. Apelin and Elabela/Toddler; double ligands for APJ/Apelin receptor in heart development, physiology, and pathology. Peptides. 2019;111:62–70.
  • Liu Y, Wang L, Shi H. The biological function of Elabela and APJ signaling in the cardiovascular system and pre-eclampsia. Hypertens Res. 2019;42(7):928–934.
  • Ho L, van Dijk M, Chye S, et al. Elabela deficiency promotes preeclampsia and cardiovascular malformations in mice. Science. 2017;357(6352):707–713.
  • Metzger BE, Gabbe SG, Persson B, International Association of Diabetes and Pregnancy Study Groups Consensus Panel, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33(7):e98–82.
  • Chng SC, Ho L, Tian J, et al. Elabela: a hormone essential for heart development signals via the apelin receptor. Dev Cell. 2013;27(6):672–680.
  • Pauli A, Norris ML, Valen E, et al. Toddler: an embryonic signal that promotes cell movement via Apelin receptors. Science. 2014;343(6172):1248636–1248636.
  • Zhang Y, Wang Y, Luo M, et al. Elabela protects against podocyte injury in mice with streptozocin-induced diabetes by associating with the PI3K/Akt/mTOR pathway. Peptides. 2019;114:29–37.
  • Sáez T, Salsoso R, Leiva A, et al. Human umbilical vein endothelium-derived exosomes play a role in foetoplacental endothelial dysfunction in gestational diabetes mellitus. Biochim Biophys Acta Mol Basis Dis. 2018;1864(2):499–508.
  • Sultan SA, Liu W, Peng Y, et al. The role of maternal gestational diabetes in inducing fetal endothelial dysfunction. J Cell Physiol. 2015;230(11):2695–2705.
  • Sobrevia L, Abarzúa F, Nien JK, et al. Review: differential placental macrovascular and microvascular endothelial dysfunction in gestational diabetes. Placenta. 2011;32 (Suppl 2):S159–S64.
  • Aslan M, Celik O, Celik N, et al. Cord blood nesfatin-1 and apelin-36 levels in gestational diabetes mellitus. Endocrine. 2012;41(3):424–429.
  • Hanssens S, Marx-Deseure A, Lecoutre S, et al. Maternal obesity alters the apelinergic system at the feto-maternal interface. Placenta. 2016;39:41–44.
  • Ryckman KK, Spracklen CN, Smith CJ, et al. Maternal lipid levels during pregnancy and gestational diabetes: a systematic review and meta-analysis. BJOG. 2015;122(5):643–651.
  • Layton J, Powe C, Allard C, et al. Maternal lipid profile differs by gestational diabetes physiologic subtype. Metabolism. 2019;91:39–42.
  • O’Harte F, Parthsarathy V, Hogg C, et al. Long-term treatment with acylated analogues of apelin-13 amide ameliorates diabetes and improves lipid profile of high-fat fed mice. PLOS One. 2018;13:e0202350.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.